Literature DB >> 21130513

Effects of multiple doses of the DPP-IV inhibitor PF-734200 on the relationship between GLP-1 and glucose in subjects with type 2 diabetes mellitus.

Stephanie M Gustavson1, Haiqing Dai, Gregory M Preston, Veena Somayaji, Boaz Hirshberg, Roberto A Calle.   

Abstract

A randomized, placebo-controlled study evaluated the effects multiple-doses (28 days) dipeptidyl peptidase-IV (DPP-IV) inhibitor PF-734200 on DPP-IV activity, glucose, glucagon-like peptide-1 (GLP-1), glucagon and insulin levels in 72 subjects with type 2 diabetes. The relationship between changes in active GLP-1 and glucose during a meal test appeared non-linear.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21130513     DOI： 10.1016/j.diabres.2010.10.018

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN： 0168-8227            Impact factor:   5.602


  2 in total

1.  The pharmacokinetics of PF-734200, a DPP-IV inhibitor, in subjects with renal insufficiency.

Authors:  Haiqing Dai; Susan L Johnson; Steven G Terra; Thomas C Marbury; William B Smith; Harry Alcorn; Rebecca A Boyd; Rong Wang; Tu T Nguyen
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

2.  Solid-phase extraction treatment is required for measurement of active glucagon-like peptide-1 by enzyme-linked immunosorbent assay kit affected by heterophilic antibodies.

Authors:  Tomonori Hasegawa; Miho Komagata; Akihiro Hamasaki; Norio Harada; Yutaka Seino; Nobuya Inagaki
Journal:  J Diabetes Investig       Date:  2018-08-20       Impact factor: 4.232
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.